F 0760
Ensure that residents are free from significant medication errors.
Level of Harm - Minimal harm
or potential for actual harm
Based on interview and record review, the facility failed to ensure residents were free from significant
medication errors for one of four sampled residents (Resident 1) when Resident 1 received
Isavuconazonium Sulfate Capsule (an antifungal medication- used to treat lung infections) every eight
hours when the physician's order from the hopsital was to receive the medication one time per day.
Residents Affected - Some
This failure resulted in Resident 1 receiving 32 extra doses of medication, which increased the potential for
adverse systemic effects and jeopardized Resident 1's health.
Resident 1 was admitted to the facility in mid-2024 with diagnoses which included allergic
bronchopulmonary aspergillosis (a fungal infection of the lung), chronic obstructive pulmonary disease
(lung disease that damages the airway and other parts of the lung making it difficult to breath) and chronic
kidney disease (damage to the kidneys that occurs over time).
During a review Resident 1's MEDICATION SUMMARY FOR PATIENT TRANSFER, dated 7/22/24, the
medication summary indicated, ISAVUCONAZONIUM SULFATE CAP [capsule], ORAL 372 MG [mg =
milligram, unit of measurement] PO [by mouth] .Note: Starting on 7/23, 372 mg .ONCE daily .
During a review Resident 1's Order Summary Report [OSR], Active Orders As Of 7/23/24, the OSR
indicated, Isavuconzonium Sulfate Oral Capsule 186 MG .Give 2 capsules orally every 8 hours for Fungal
Infection .
During a review of Progress Notes [PN] Type: Physician's Order Note, dated 7/22/24 at 5:40 p.m., the PN
indicated, Note text: This order is outside of the recommended dose of frequency .Isavuconazonium Sulfate
Capsule .the daily dose of 6 capsules exceeds theusual [sic] dose .the frequency of 3 times per day
exceeds the usual frequency of every 7 days to daily .
During a review of Resident 1's Medication Administration Record (MAR), dated 7/1/24-7/31/24, the MAR
indicated, Isavuconzonium Sulfate Oral Capsule 186 MG .Give 2 capsules orally every 8 hours for Fungal
Infection . Resident 1 received 18 more doses than ordered by the physician from 7/23-7/31/24.
During a review of Resident 1's Medication Administration Record (MAR), dated 8/1/24-8/31/24, the MAR
indicated, Isavuconzonium Sulfate Oral Capsule 186 MG .Give 2 capsules orally every 8 hours for Fungal
Infection . Resident 1 received 14 more doses than ordered by the physician from 8/1-8/7/24.
During a review of PN Type: Physician's Order Note, dated 8/8/24 at 12:18 p.m., the PN indicated, .this
writer .investigated and found the medication [Isavuconzonium Sulfate] as to be give [sic] once per day. the
[sic] order was put into the system as 2 cap Q 8 hr [hour] .the discharge summary states that the
medication is to be daily starting on 7/23/24 .
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 3
Event ID:
055886
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
055886
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/14/2024
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Roseville Care Center
1161 Cirby Way
Roseville, CA 95661
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0760
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
During a review of PN Type: Nurse's Note, dated 8/8/24 at 4:15 p.m., the PN indicated, Patient is his own
RP [responsible party] and has been informed about the medication error regarding the incorrect dosing.
Order has been changed and physician ordered CMP [Comprehensive Metabolic Panel, blood test to
screen for a range of potential health problems] and liver function test .
During a review of the manufactures insert and recommendations for Isavuconzonium Sulfate titled,
HIGHLIGHTS OF PRESCRIBING INFORMATION, undated, the recommendations indicated,
Recommended Dosage .in adult patients .Two 186 mg capsules [372 mg] orally once daily OVERDOSAGE:
During clinical studies the total daily CRESEMBA [brand name of Isavuconzonium Sulfate] doses higher
than the recommended dose regimen were associated with an increased rate of adverse reactions. At
supratherapeutic doses [three times the recommended maintenance dose] .there were proportionally more
treatment-emergent adverse reactions than in the therapeutic dose .
During a concurrent interview and record review on 8/14/24 at 11:07 a.m. with the Assistant Director of
Nursing (ADON) of Resident 1's electronic health record (EHR), the ADON confirmed the admission
hospital orders indicated Isavuconazonium was to be administered once a day. The ADON confirmed the
MAR indicated Isavuconazonium had been administered every eight hours.
When asked if Resident 1's orders were correctly entered into the EHR, the ADON stated, No. When asked
if Resident 1 received the incorrect dosage of medication from 7/23/24 until 8/8/24, the ADON stated, Yes.
During an interview on 8/14/24 at 11:32 a.m. with the DON, the DON confirmed Resident 1's physician
orders from the hospital for Isavuconazonium were not correctly entered or followed. The DON confirmed
Resident 1 received the wrong dose of medication. When asked why it was important to give the correct
dose of medication the DON stated, .you need to give the right dose to cure .make sure you are not
overdosing because it can lead to adverse effects .
During an interview on 8/14/24 at 11:44 a.m. with the Pharmacist (PHARM) 1, the PHARM 1 was able to
access Resident 1's physician orders and confirmed the orders indicated the medication was entered into
the MAR to be administered every eight hours from 7/23/24 until 8/8/24. The PHARM 1 was asked about
recommended dosing for Isavuconazonium. PHARM 1 stated, The initial dose was 372 mg every eight
hours for six doses and then 372 mg once daily .the dose for [Resident 1] was higher than the
recommended dose.
During a concurrent interview and record review on 8/14/24 at 12:25 p.m. with the ADON, the ADON was
asked to review the PN Type: Physician's Note for Resident 1, dated 7/22/24 which indicated, .This order is
outside of the recommended dose of frequency .Isavuconazonium Sulfate Capsule . The ADON stated the
Physician Note was, .an automated system generated warning from [charting program]. When asked if
there was any follow up to the note regarding the medication amount being outside the recommended
dose, the ADON stated, No one acted upon it. There was no follow up.
During an interview on 8/15/24 at 12:41 p.m. with the Physician's Assistant (PA), the PA was asked about
the PN Type: Physician's Note for Resident 1 on 7/22/24. The PA stated, .as a provider we don't see those
notes .
During a review of the facility's policy and procedure (P&P) titled, Adverse Consequences and Medication
Errors, dated 2/23, the P&P indicated, .Residents receiving medications are monitored for adverse
consequences .When a resident receives a new medication order, review the following .the dose
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
055886
If continuation sheet
Page 2 of 3
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
055886
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/14/2024
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Roseville Care Center
1161 Cirby Way
Roseville, CA 95661
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0760
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
FORM CMS-2567 (02/99)
Previous Versions Obsolete
.and monitoring are in agreement with current clinical practice, clinical guidelines, and/or manufacturer's
specifications for use .
During a review of the facility's P&P titled, Reconciliation of Medications on Admission, dated 7/17, the P&P
indicated, .The purpose of this procedure is to ensure medication safety by accurately accounting for the
resident's medications, routes and dosages upon admission or readmission to the facility .Medication
reconciliation helps to ensure that medications, routes and dosages have been accurately communicated to
the Attending Physician and care team .If there is a discrepancy or conflict in medications, dose, route or
frequency, determine the most appropriate action to resolve the discrepancy .
Event ID:
Facility ID:
055886
If continuation sheet
Page 3 of 3